A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer

Cancer Commun (Lond). 2023 Jan;43(1):150-153. doi: 10.1002/cac2.12379. Epub 2022 Nov 4.

Yang Zhang^{1

2}, Zi-Xian Wang^{3

2}, Lin Shen⁴, Jin Li⁵, Jing Huang⁶, Wei-Guo Su⁷, Dong-Sheng Zhang^{3

2}, Rui-Hua Xu^{3

2}

¹ Department of Clinical Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
² Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
³ Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
⁴ Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
⁵ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, P. R. China.
⁶ Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.
⁷ HUTCHMED limited, Shanghai, P. R. China.

No abstract available

Publication types